Executive Director, Investor Relations and Corporate Communications

Company Overview Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. Position Overview The Executive Director, Investor Relations will serve as the primary point of contact for the investment community and play a critical role in shaping Immunome’s external communications strategy. Reporting to the Chief Financial Officer, this leader will be responsible for articulating the company’s strategy, progress, and value proposition to investors, analysts, and other key financial stakeholders. The role requires deep understanding of the biotechnology sector and the ability to translate complex scientific and clinical information into clear, compelling narratives that enhance Immunome’s visibility and credibility in the capital markets. Responsibilities Investor Relations Execute the investor relations program in partnership with the CEO and CFO, ensuring clear, consistent, and disciplined communication with the capital markets. Own day-to-day IR execution, including investor and analyst meeting coordination, targeting support, CRM management, feedback capture, and follow-up. Draft all core IR materials, including investor presentations, fact sheets, FAQs, earnings scripts, Q&A documents, and conference talk tracks. Serve as the primary point of contact for sell-side analysts on logistics and clarifications; proactively identify and correct misinterpretations. Coordinate investor conferences, non-deal roadshows, and other capital markets engagements. Track, synthesize, and report investor sentiment and market feedback to senior management and the Board. Corporate Communications Lead execution of the corporate communications function, with direct responsibility for drafting press releases, corporate updates, pipeline and clinical announcements, and reactive statements. Translate complex scientific, clinical, and regulatory information into clear, accurate, and investable external messaging. Partner closely with Legal and senior management to ensure Reg FD compliance, disclosure discipline, and appropriate risk framing. Manage PR and IR agencies, setting direction and maintaining a high bar for accuracy, clarity, and quality. Support media engagement and spokesperson preparation; manage inbound media inquiries as needed. Ensure consistency across all external-facing materials and channels. Cross-functional leadership Serve as the central point of coordination for external messaging across Finance, Clinical, Regulatory, Legal, and Business Development. Own the external communications calendar and disclosure cadence. Identify communication risks early and escalate judgment calls appropriately. Support special situations, including clinical data releases, financings, and issues management. Qualifications A minimum of 10 years of experience in investor relations, corporate communications, or a closely related role within biotech, biopharma, or life sciences, or equivalent experience. Public company experience, including direct involvement in earnings preparation and material disclosures. Demonstrated ability to independently draft high-quality press releases, investor materials, and executive-level communications. Strong scientific literacy, with the ability to understand and accurately communicate clinical data and development strategy. Strong financial literacy a…